[go: up one dir, main page]

MA43082A1 - Conjugue d'enzymes thérapeutiques - Google Patents

Conjugue d'enzymes thérapeutiques

Info

Publication number
MA43082A1
MA43082A1 MA43082A MA43082A MA43082A1 MA 43082 A1 MA43082 A1 MA 43082A1 MA 43082 A MA43082 A MA 43082A MA 43082 A MA43082 A MA 43082A MA 43082 A1 MA43082 A1 MA 43082A1
Authority
MA
Morocco
Prior art keywords
conjugate
therapeutic enzymes
immunoglobulin
connecting portion
relates
Prior art date
Application number
MA43082A
Other languages
English (en)
Inventor
Dae Jin Kim
Jung Kuk Kim
Sung Youb Jung
Se Chang Kwon
Original Assignee
Hanmi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharma Co Ltd filed Critical Hanmi Pharma Co Ltd
Publication of MA43082A1 publication Critical patent/MA43082A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/328—Polymers modified by chemical after-treatment with inorganic compounds containing other elements
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un ensemble de couplage dans lequel une région fc d'immunoglobuline est couplée à des enzymes thérapeutiques à travers une partie de connexion de polymère non peptidique, et concerne : un ensemble de couplage dans lequel une partie de connexion de polymère non peptidique est spécifiquement couplée à un fc d'immunoglobuline; son procédé de production; et une composition le contenant.
MA43082A 2016-01-29 2017-01-31 Conjugue d'enzymes thérapeutiques MA43082A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160011886 2016-01-29
PCT/KR2017/001016 WO2017131496A1 (fr) 2016-01-29 2017-01-31 Ensemble de couplage pour enzymes thérapeutiques

Publications (1)

Publication Number Publication Date
MA43082A1 true MA43082A1 (fr) 2018-10-31

Family

ID=59398822

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43082A MA43082A1 (fr) 2016-01-29 2017-01-31 Conjugue d'enzymes thérapeutiques

Country Status (23)

Country Link
US (1) US10918736B2 (fr)
EP (1) EP3409771A4 (fr)
JP (2) JP7356222B2 (fr)
KR (1) KR20170091056A (fr)
CN (1) CN108884455A (fr)
AR (2) AR107483A1 (fr)
AU (1) AU2017210871A1 (fr)
BR (1) BR112018015603A2 (fr)
CA (1) CA3012982A1 (fr)
CL (2) CL2018002045A1 (fr)
CO (1) CO2018008427A2 (fr)
CR (1) CR20180393A (fr)
EA (1) EA201891573A1 (fr)
EC (1) ECSP18062538A (fr)
HK (1) HK1257558A1 (fr)
MA (1) MA43082A1 (fr)
MX (1) MX2018009266A (fr)
PH (1) PH12018501612A1 (fr)
SG (1) SG11201806502UA (fr)
TN (1) TN2018000270A1 (fr)
TW (1) TW201729846A (fr)
WO (1) WO2017131496A1 (fr)
ZA (1) ZA201805634B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MY197218A (en) 2015-07-06 2023-06-02 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
BR112018077362A2 (pt) 2016-07-01 2019-10-01 The Board Of Trustees Of The Leland Stanford Junior University conjugados para edição de superfície de célula-alvo
WO2018105988A1 (fr) 2016-12-05 2018-06-14 한미약품 주식회사 Conjugué ayant une réponse immunitaire atténuée
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
TWI832818B (zh) * 2017-07-07 2024-02-21 南韓商韓美藥品股份有限公司 新穎的治療性酵素融合蛋白及其用途
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
WO2019124973A1 (fr) * 2017-12-19 2019-06-27 재단법인 목암생명과학연구소 Conjugué de protéine et protéine de fusion qui comprennent de l'albumine et une enzyme lysosomale
EA202091239A1 (ru) * 2017-12-22 2020-09-09 Ханми Фарм. Ко., Лтд. Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
EP3735458A4 (fr) 2018-01-03 2022-04-27 Palleon Pharmaceuticals Inc. Sialidases humaines recombinantes, protéines de fusion de sialidase et leurs méthodes d'utilisation
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2019222663A1 (fr) 2018-05-17 2019-11-21 Regeneron Pharmaceuticals, Inc. Anticorps anti-cd63, conjugués et leurs utilisations
CN111971387A (zh) 2018-07-25 2020-11-20 阿特根公司 新型透明质酸水解酶突变体和包含其的药物组合物
AU2019377456A1 (en) 2018-11-07 2021-05-27 Merck Sharp & Dohme Llc Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
KR20210100794A (ko) 2020-02-06 2021-08-18 삼성디스플레이 주식회사 표시 모듈 가공 장치 및 표시 모듈 가공 방법
CN115427562B (zh) 2020-08-07 2025-05-09 阿特根公司 制备重组玻尿酸酶的方法
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
KR20220065720A (ko) * 2020-11-13 2022-05-20 한미약품 주식회사 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도
WO2022103221A1 (fr) * 2020-11-13 2022-05-19 한미약품 주식회사 Utilisation d'une protéine de fusion d'une enzyme thérapeutique pour prévenir et traiter une maladie rénale provoquée par la maladie de fabry ou l'accompagnant
WO2025137213A1 (fr) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes alpha-glucosidase acides et méthodes associées

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
BRPI0811637B8 (pt) * 2007-05-30 2021-05-25 Genexine Inc proteínas de fusão da imunoglobulina
WO2011049737A1 (fr) 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Nouvelles compositions pour prévenir et/ou traiter des troubles du stockage lysosomique
RU2018104472A (ru) * 2011-03-18 2019-02-22 Джензим Корпорейшн Ингибиторы глюкозилцерамид-синтазы
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
KR101895634B1 (ko) 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
WO2015009052A1 (fr) 2013-07-16 2015-01-22 일동제약 주식회사 Protéine de fusion de fc hybride d'immunoglobuline et d'enzyme
EA036394B1 (ru) * 2013-10-24 2020-11-05 ЮНИКЬЮРЕ АйПи Б.В. Псевдотипированный вектор на основе аденоассоциированного вируса aav-5 для генной терапии неврологических заболеваний
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas

Also Published As

Publication number Publication date
WO2017131496A1 (fr) 2017-08-03
CN108884455A (zh) 2018-11-23
US10918736B2 (en) 2021-02-16
JP2019506164A (ja) 2019-03-07
CO2018008427A2 (es) 2018-10-31
AR107483A1 (es) 2018-05-02
AR120515A2 (es) 2022-02-23
TN2018000270A1 (en) 2020-01-16
ECSP18062538A (es) 2018-09-30
CL2018002045A1 (es) 2018-08-31
EP3409771A1 (fr) 2018-12-05
EA201891573A1 (ru) 2019-02-28
CL2020001857A1 (es) 2020-10-02
AU2017210871A1 (en) 2018-08-30
MX2018009266A (es) 2019-01-10
BR112018015603A2 (pt) 2018-12-26
HK1257558A1 (en) 2019-10-25
SG11201806502UA (en) 2018-08-30
ZA201805634B (en) 2019-06-26
JP7356222B2 (ja) 2023-10-04
TW201729846A (zh) 2017-09-01
CA3012982A1 (fr) 2017-08-03
JP2022046524A (ja) 2022-03-23
US20190046657A1 (en) 2019-02-14
CR20180393A (es) 2019-02-12
KR20170091056A (ko) 2017-08-08
PH12018501612A1 (en) 2019-04-08
EP3409771A4 (fr) 2019-10-23

Similar Documents

Publication Publication Date Title
MA43082A1 (fr) Conjugue d'enzymes thérapeutiques
MA40662A1 (fr) Anticorps contre tigit
WO2019004778A3 (fr) Nouveau mutant d'aspartokinase et procédé de production d'acide l-aminé l'utilisant
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
MA31984B1 (fr) Formulation d'anticorps
MY201701A (en) Optimized antibody compositions for treatment of ocular disorders
MA43518B1 (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
MA39225A1 (fr) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
PE20110382A1 (es) Tratamiento de enfermedad autoinmunitaria e inflamatoria
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
MA31904B1 (fr) Anticorps bispecifiques bivalents
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA38176A1 (fr) Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
FR3029790B1 (fr) Microbille d'hydrogel de chitosane
MA35359B1 (fr) Lutte biologique contre les nématodes
MA46459B1 (fr) Méthode de traitement de lésions rénales aiguës
MA38296B2 (fr) Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations
PE20091969A1 (es) ANTICUERPOS ANTI-PirB
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
FR3056398B1 (fr) Ventouse de massage
MA45831B1 (fr) Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation
FR3002143B1 (fr) Composition cosmetique comprenant un copolymere vinylformamide / vinylformamine, un polymere epaississant cellulosique et un tensioactif amphotere ou zwitterionique
FR3062850B1 (fr) Procede de preparation monotope de composes organo-iodes